Business & Industry

Eli Lilly, the US pharma giant, has become the first drugmaker to hit $1tn valuation on November 22, 2025, hence entering the exclusive club, which is so far dominated by technology giants, highlighting its rise as a weight-loss powerhouse. The...

Samsung Biologics announced on November 26, 2025, that it has gone on to achieve a whopping 400 regulatory manufacturing approvals all over the world due to its quality competitiveness. It is worth noting that as of November 2025, Samsung Biologics has secured...

It should not be termed as an overstatement when we say that Maryland is fast becoming the home away from home when it comes to AstraZeneca, the British drugmaker. On November 21, the biopharma powerhouse pushed it up a...

The Australian-based biopharma company, CSL, plans to invest almost $1.5 billion in the next five years so as to expand its presence in the U.S. However, this is going to be subject to the approval from the board of...

The news of Pfizer to acquire Metsera in a $10bn deal has indeed caught the eye of many. Metsera happens to be a US-based biotechnology firm and the deal was indeed a result of a heated bidding battle against...

European venture capital firm Sofinnova Partners said on November 17 that it raised 650 million euros, equivalent to $750 million, for a new fund that is going to support the present and upcoming life sciences companies. It is well to be...

Johnson & Johnson will be paying $3.05 billion so as to acquire Halda Therapeutics, thereby getting a novel cell death platform while at the same time also strengthening its prostate cancer franchise that’s built on Erleada. At the mainstay of the...